All In Biotech

Drug Trial Radar · NCT05150340

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects With Primary Immunodeficiency Diseases (PID)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16

Actual

Start

Jan 24, 2022

Primary completion

Aug 28, 2023

Study completion Aug 28, 2023

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to check how much TAK-771 stays in their blood over time, side effect from the study treatment or TAK-771, how much TAK-771 participants can receive without getting side effects from it, and if TAK-771 improves symptoms of primary immunodeficiency diseases (PID). This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-771 for totally 27 or 30 weeks. Treatment period is consist of two periods called Epoch 1 and Epoch 2. In Epoch 1, different groups of participants will receive lower to higher doses of TAK-771 for 3 to 6 weeks. The study doctors will check for side effects from each dose of TAK-771. In Epoch 2, participants will receive TAK-771 once a 3 or 4 weeks until the end of 24 weeks. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 3, or 4 weeks).

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

  • TAK-771Drug

    Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Kyushu University Hospital

    Fukuoka, Japan

  • Gifu University Hospital

    Gifu, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Saitama Prefectual Children's Medical Center

    Saitama, Japan

  • Shizuoka Childrens Hospital

    Shizuoka, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Hospital of University of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, Japan

  • Shinshu University Hospital

    Matsumoto, Nagano, Japan

  • Tokyo Medical Dental University Hospital

    Bunkyo-ku, Tokyo, Japan

  • National Center for Child Health and development

    Setagaya-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.